Search Results
Oct 13, 2025, 12:02 ET Health Enterprise Partners Announces Second Annual RISE Above Award Winner
Patrick McGrath, PhD, Chief Clinical Officer of NOCD to be honored for his leadership and commitment to clinical innovation NEW YORK, Oct.
More news about: Health Enterprise Partners
Oct 13, 2025, 09:30 ET NORD Breakthrough Summit Features Bold New Ideas for the Future of Rare Disease Care, Policy and Research
Partnering for Education at a Turning Point in the Desmoid Tumor Landscape(Presenting Author: Tariqa Ackbarali, PhD, CHCP, Medlive)This case study explores the power of partnership through a collaboration among Medlive, NORD, and the Desmoid Tumor Research
More news about: National Organization for Rare Disorders (NORD®)
Oct 13, 2025, 09:00 ET Solugen and American Rheinmetall Munitions Partner to Make American Energetics More Affordable
committed to helping the defense community secure resilient, U.S.-based supply chains while bending the cost curve for next-gen energetics," said Sean Hunt, PhD, co-founder and Chief Technology Officer of Solugen. "By collaborating with ARM—and with other leaders across the sector—we're building pathways that
More news about: Solugen Inc.
Oct 13, 2025, 08:00 ET Vasa Therapeutics Receives FDA IND Clearance to Advance Novel Small Molecule VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
VS-041 is the first step to evaluate prospectively the therapeutic impact of interrupting the generation of endotrophin, " said Julio Chirinos, MD, PhD, Professor of Medicine in the Cardiovascular Division at the Perelman School of Medicine at the University of Pennsylvania, an expert in HFpEF and endotrophin,
More news about: Vasa Therapeutics
Oct 13, 2025, 07:00 ET Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting
Samarendra Mohanty, PhD, President, and Chief Scientific Officer Nanoscope Therapeutics; and
More news about: Nanoscope Therapeutics
Oct 13, 2025, 07:00 ET Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
durability data reinforce that PAPZIMEOS is not only a medical breakthrough but a transformative therapy for the RRP community," said Helen Sabzevari, PhD, President and CEO of Precigen. "For patients and their families, sustained responses mean freedom from the relentless cycle of repeat surgeries, reduction
More news about: Precigen, Inc.
Oct 13, 2025, 06:00 ET ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease
one of the most prevalent inherited peripheral neuropathies in the world, yet effective disease-modifying therapies remain elusive," said Paul August, PhD, Chief Scientific Officer of ReviR Therapeutics, and a leading expert in neurodegenerative disease therapeutics. "The progressive nature of CMT is characterized
More news about: ReviR Therapeutics
Oct 13, 2025, 05:00 ET Faculty Launches Frontier 3: The Next Evolution in Decision Intelligence for Enterprises Worldwide
Faculty works with top AI labs - including OpenAI and Anthropic, to ensure that cutting-edge models are safe, explainable, and human-led. The company's PhD-heavy team has delivered hundreds of real-world AI projects across the public and private sectors. Faculty remains founder-led and is backed by investors
More news about: Aspectus Group
Oct 13, 2025, 04:00 ET Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of Neuropsychopharmacology Congress
for derisking clinical programs earlier in development." On October 21st, Dr. Aaron Koenig will join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience, for a webinar titled "Neuropsychiatry Clinical Trials: Evolving with Portable EEG and Digital Endpoints,"
More news about: Cumulus Neuroscience
Oct 11, 2025, 09:30 ET LAS PERSONAS QUE RECIBEN MENOS SEDACIÓN CUANDO DEPENDEN DE UN RESPIRADOR TIENEN MÁS PROBABILIDADES DE VOLVER A LLEVAR UNA VIDA AUTÓNOMA TRAS LA HOSPITALIZACIÓN
PhD, 112 estudiantes en el programa combinado de MD/PhD y aproximadamente
More news about: Montefiore Health System
Oct 10, 2025, 19:09 ET MindClay Brings "Interactive Museum" Wellness Lounge to Behavioral Health Tech 2025 in San Diego
Featured speakers at the conference: Chris DeCou, PhD, Director of Amazon Health Benefits, Amazon Sandy Balwan, MD, Chief Medical Officer, Northwell
More news about: MindClay
Oct 10, 2025, 16:43 ET PONANT EXPLORATIONS GROUP ANNOUNCES NEW PARTNERSHIP WITH WOODS HOLE OCEANOGRAPHIC INSTITUTION (WHOI), THE WORLD'S LEADING ORGANIZATION DEDICATED TO OCEAN RESEARCH, EXPLORATION, AND EDUCATION
throughout the year, as well as on select sailings aboard other ships. This is made possible by its many partnerships and initiatives, which include two PhD students it finances. To date, the company has earned 10 citations in peer-reviewed publications for its support in data collection and research.
More news about: PONANT EXPLORATIONS GROUP
Oct 10, 2025, 15:31 ET Alamar Biosciences Luncurkan NULISAqpcr™ BD-pTau217 Assay: Terobosan Deteksi Biomarker Non Invasif Khusus Otak Untuk Penelitian Penyakit Alzheimer
dengan presisi lebih tinggi." "Kinerja Alamar atas pTau217 assay plasma khusus otak sungguh luar biasa," kata Jonathan Schott, MD, PhD, Profesor Neurologi di University College London. "Untuk mendeteksi patologi Alzheimer dengan gejala kognitif, hasil awal kami menunjukkan bahwa kinerja
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:11 ET Společnost Alamar Biosciences uvádí na trh test NULISAqpcr™ BD-pTau217: průlom v neinvazivní detekci biomarkerů specifických pro mozek v rámci výzkumu Alzheimerovy choroby
s vyšší přesností." „Výkon testů pTau217 společnosti Alamar specifických pro mozek je vynikající," uvedl Jonathan Schott, MD, PhD, profesor neurologie na University College London. „Pokud jde o detekci Alzheimerovy patologie s kognitivními symptomy, naše předběžné výsledky naznačují,
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:06 ET Alamar Biosciences uvádza na trh test NULISAqpcr™ BD-pTau217: Prevratnú novinku v neinvazívnej detekcii biomarkerov špecifických pre mozog na výskum Alzheimerovej choroby
presnosťou." „Výkonnosť testov pTau217 pre plazmu špecifickú pre mozog od spoločnosti Alamar je vynikajúca," povedal Jonathan Schott, MD, PhD, profesor neurológie na University College London. „Naše rané výsledky naznačujú, že pri detekcii patológie Alzheimerovej choroby s kognitívnymi príznakmi
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 13:46 ET Alamar Biosciences bringt NULISAqpcr™ BD-pTau217 Assay auf den Markt: Durchbruch beim nicht-invasiven, hirnspezifischen Biomarker-Nachweis für die Alzheimer-Forschung
Präzision erkennen." „Die Leistung der hirnspezifischen pTau217-Plasmatests von Alamar ist ausgezeichnet", sagt Jonathan Schott, MD, PhD, Professor für Neurologie am University College London. „Für den Nachweis von Alzheimer-Pathologie mit kognitiven Symptomen deuten unsere ersten Ergebnisse
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 12:35 ET Alamar Biosciences lance le test NULISAqpcr™ BD-pTau217 : une avancée dans la détection non invasive de biomarqueurs spécifiques au cerveau pour la recherche sur la maladie d'Alzheimer
« La performance des dosages de pTau217 dans le plasma spécifique au cerveau d'Alamar est excellente », déclare Jonathan Schott, MD, PhD, professeur de neurologie à l'University College London. « Pour la détection de la pathologie d'Alzheimer avec des symptômes cognitifs, nos premiers
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 09:00 ET Foundation Fighting Blindness Marks World Mental Health Day with Upcoming Webinar for Eye Care Professionals: Seeing Beyond Vision Loss - A Focus on Mental Health Resources for Patients with Retinal Disease
2025, will feature presentations from patient advocate Jessie Wolinsky, retina specialist Sandeep Grover, MD, and clinical psychologist Ann Wagner, PhD, LP, ABPP. COLUMBIA, Md., Oct.
More news about: Foundation Fighting Blindness
Oct 10, 2025, 07:48 ET Alamar Biosciences lanza el ensayo NULISAqpcr™ BD-pTau217 para la investigación de la enfermedad de Alzheimer
"El rendimiento de los ensayos de pTau217 plasmáticos específicos del cerebro de Alamar es excelente", afirmó Jonathan Schott, MD, PhD, profesor de Neurología del University College de Londres. "Para la detección de la patología de Alzheimer con síntomas cognitivos, nuestros primeros
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 02:00 ET Renalys Announces Completion of Primary Endpoint Data Collection for Phase III Clinical Trial of Sparsentan for Iga Nephropathy in Japan
Company Name: Renalys Pharma, Inc.Address: 3-11, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, JapanRepresentative: BT Slingsby, MD, PhD, MPHEstablished: April 2023URL: https://renalys.com/
More news about: Renalys Pharma, Inc.
Oct 09, 2025, 17:14 ET Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research
higher precision." "The performance of Alamar's brain-specific plasma pTau217 assays is excellent," said Jonathan Schott, MD, PhD, Professor of Neurology, University College London. "For the detection of Alzheimer's pathology with cognitive symptoms, our early results suggest that
More news about: Alamar Biosciences, Inc.
Oct 09, 2025, 16:54 ET Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research
higher precision." "The performance of Alamar's brain-specific plasma pTau217 assays is excellent," said Jonathan Schott, MD, PhD, Professor of Neurology, University College London. "For the detection of Alzheimer's pathology with cognitive symptoms, our early results suggest that
More news about: Alamar Biosciences, Inc.
Oct 09, 2025, 16:15 ET Endo Announces Nine New and Modified Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting
Authors: Irwin Goldstein, MD; Sue W. Goldstein, CSE, CCRC, IF; Rose Hartzell-Cushanick, PhD, EdS; Tami Rowen, MD; Sameena Rahman, MD; Becky Lynn, MD; Alyse Kelly-Jones, MD; David Hurley, MD; Nicole Tay, MS; Sheryl Kingsberg, PhD Treatment Patterns for Peyronie's Disease (PD):
More news about: Endo USA, Inc.
Oct 09, 2025, 11:41 ET Nootropics Depot's Erinamax Sets Industry Benchmark with Market-Leading Erinacine A Standardization
(COAs), and lab testing results available on every product page. In addition, they have formed a Scientific Advisory Board with board certified doctors, PhD researchers, and botanists to ensure that consumers can trust that scientific rigor is being upheld in everything they do. Nootropics Depot's newly redesigned
More news about: Nootropics Depot
Oct 09, 2025, 10:25 ET NEW BOOK, examines pharmaceutical policy in Canada and its impact on patients, taxpayers, innovation, and trade relations with the United States
pharmaceutical policy a non-tariff barrier to trade? In Building Better Pharma Policy in Canada, author Brett J Skinner, PhD, founder and CEO of the Canadian Health Policy Institute, offers evidence-based answers to these, and other intriguing questions.
More news about: Canadian Health Policy Institute